Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database

被引:70
作者
Blin, P. [1 ,2 ]
Lassalle, R. [1 ,2 ]
Dureau-Pournin, C. [1 ,2 ]
Ambrosino, B. [1 ,2 ]
Bernard, M. A. [1 ,2 ]
Abouelfath, A. [1 ,2 ]
Gin, H. [3 ,4 ]
Le Jeunne, C. [5 ]
Pariente, A. [1 ,2 ,3 ,6 ]
Droz, C. [1 ,2 ,6 ]
Moore, N. [1 ,2 ,3 ,6 ]
机构
[1] Univ Bordeaux, Dept Pharmacol, F-33076 Bordeaux, France
[2] Inserm CIC P0005, Bordeaux, France
[3] CHU Bordeaux, Bordeaux, France
[4] Univ Bordeaux Segalen, Bordeaux, France
[5] Hop Hotel Dieu, Paris, France
[6] Inserm U657, Bordeaux, France
关键词
Cancer; Cohort study; Database study; Human insulin; Insulin glargine; Sulfonylureas; Type; 2; diabetes; BODY-MASS INDEX; INTENSIVE GLYCEMIC CONTROL; SHORT-TERM INCIDENCE; GLUCOSE CONTROL; TYPE-2; MORTALITY; ANALOGS; PROLIFERATION; MALIGNANCIES; BREAST;
D O I
10.1007/s00125-011-2429-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Using the Echantillon G,n,raliste de B,n,ficiaires: random 1/97 permanent sample of the French national healthcare insurance system database (EGB), we investigated whether, as previously suspected, the risk of cancer in insulin glargine (A21Gly,B31Arg,B32Arg human insulin) users is higher than in human insulin users. The investigation period was from 1 January 2003 to 30 June 2010. We used Cox proportional hazards time-dependent models that were stratified on propensity score quartiles for use of insulin glargine vs human insulin, and adjusted for insulin, biguanide and sulfonylurea possession rates to assess the risk of cancer or death in all or incident exclusive or predominant (>= 80% use time) users of insulin glargine compared with equivalent human insulin users. Only type 2 diabetic patients were studied. Exposure rates varied from 2,273 and 614 patient-years for incident exclusive users of insulin glargine or human insulin, respectively, to 3125 and 2341 patient-years for all patients predominantly using insulin glargine or human insulin, respectively. All-type cancer HRs with insulin glargine vs human insulin ranged from 0.59 (95% CI 0.28, 1.25) in incident exclusive users to 0.58 (95% CI 0.34, 1.01) in all predominant users. Cancer risk increased with exposure to insulin or sulfonylureas in these patients. Adjusted HRs for death or cancer associated with insulin glargine compared with human insulin ranged from 0.58 (95% CI 0.32, 1.06) to 0.56 (95% CI 0.36, 0.87). There was no excess risk of cancer in type 2 diabetic patients on insulin glargine alone compared with those on human insulin alone. The overall risk of death or cancer in patients on insulin glargine was about half that of patients on human insulin, thereby excluding a competitive risk bias.
引用
收藏
页码:644 / 653
页数:10
相关论文
共 45 条
[31]   Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients - A retrospective cohort study [J].
Monami, M. ;
Lamanna, C. ;
Pala, L. ;
Bardini, G. ;
Cresci, B. ;
Francesconi, P. ;
Balzi, D. ;
Marchionni, N. ;
Rotella, C. M. ;
Mannucci, E. .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2008, 116 (03) :184-189
[32]   Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients [J].
Monami, Matteo ;
Colombi, Claudia ;
Balzi, Daniela ;
Dicembrini, Ilaria ;
Giannini, Stefano ;
Melani, Cecilia ;
Vitale, Valentina ;
Romano, Desiderio ;
Barchielli, Alessandro ;
Marchionni, Niccolo ;
Rotella, Carlo Maria ;
Mannucci, Edoardo .
DIABETES CARE, 2011, 34 (01) :129-131
[33]   Sulphonylureas and cancer: a case-control study [J].
Monami, Matteo ;
Lamanna, Caterina ;
Balzi, Daniela ;
Marchionni, Niccolo ;
Mannucci, Edoardo .
ACTA DIABETOLOGICA, 2009, 46 (04) :279-284
[34]   Insulin glargine and malignancy: an unwarranted alarm [J].
Pocock, Stuart J. ;
Smeeth, Liam .
LANCET, 2009, 374 (9689) :511-513
[35]   Incident cancer burden attributable to excess body mass index in 30 European countries [J].
Renehan, Andrew G. ;
Soerjomataram, Isabelle ;
Tyson, Margaret ;
Egger, Matthias ;
Zwahlen, Marcel ;
Coebergh, Jan Willem ;
Buchan, Iain .
INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (03) :692-702
[36]   Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis? [J].
Rensing, K. L. ;
Bloemendaal, F. M. Houttuijn ;
Weijers, E. M. ;
Richel, D. J. ;
Buller, H. R. ;
Koolwijk, P. ;
van der Loos, C. M. ;
Twickler, Th. B. ;
von der Thusen, J. H. .
DIABETOLOGIA, 2010, 53 (05) :966-970
[37]   Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study [J].
Rosenstock, J. ;
Fonseca, V. ;
McGill, J. B. ;
Riddle, M. ;
Halle, J. P. ;
Hramiak, I. ;
Johnston, P. ;
Davis, M. .
DIABETOLOGIA, 2009, 52 (09) :1971-1973
[38]  
Schienkiewitz A, 2006, AM J CLIN NUTR, V84, P427
[39]   Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines [J].
Shukla, Ashish ;
Grisouard, Jean ;
Ehemann, Volker ;
Hermani, Alexander ;
Enzmann, Harald ;
Mayer, Doris .
ENDOCRINE-RELATED CANCER, 2009, 16 (02) :429-441
[40]   Diabetes mellitus, hyperglycaemia and cancer [J].
Simon, D. ;
Balkau, B. .
DIABETES & METABOLISM, 2010, 36 (03) :182-191